Table 3.

Stratified analyses of the association between statin use and the risk of liver-related events.

Variable		Statin	At risk, n	Events, n	Rate∗	Adjusted HR (95% CI)
Age group	40-64	Non-user	361,231	5,940	165.03	Reference (1.00)
		Statin user	96,018	1,287	134.69	0.64 (0.60–0.68)
	≥65	Non-user	41,991	2,129	537.23	Reference (1.00)
		Statin user	17,335	554	335.05	0.63 (0.57–0.70)
Sex	Male	Non-user	352,970	6,734	192.27	Reference (1.00)
		Statin user	50,252	1,335	270.63	0.66 (0.62–0.70)
	Female	Non-user	88,072	1,407	161.39	Reference (1.00)
		Statin user	25,281	434	174.27	0.6 (0.53–0.67)
Hypertension	No	Non-user	212,457	3,230	152.55	Reference (1.00)
		Statin user	34,958	480	138.09	0.64 (0.58–0.71)
	Yes	Non-user	190,765	4,839	257.64	Reference (1.00)
		Statin user	78,395	1,361	176.01	0.63 (0.59–0.67)
Diabetes	No	Non-user	327,219	5,246	161.22	Reference (1.00)
		Statin user	76,003	2,823	380.61	0.7 (0.65–0.76)
	Yes	Non-user	67,478	885	132.02	Reference (1.00)
		Statin user	45,875	956	212.2	0.59 (0.55–0.63)
LC	No	Non-user	400,004	6,205	156.36	Reference (1.00)
		Statin user	112,475	1,424	127.96	0.62 (0.59–0.66)
	Yes	Non-user	3,218	1,864	6,832.16	Reference (1.00)
		Statin user	878	417	5,196.42	0.68 (0.61–0.76)
BMI	<25	Non-user	49,433	2,200	453.94	Reference (1.00)
		Statin user	12,695	405	323.49	0.57 (0.51–0.64)
	≥25	Non-user	353,789	5,869	167.16	Reference (1.00)
		Statin user	100,658	1,436	144.23	0.63 (0.59–0.67)
Abnormal ALT	No	Non-user	186,499	2,046	110.65	Reference (1.00)
		Statin user	49,855	556	112.93	0.8 (0.73–0.88)
	Yes	Non-user	216,723	6,023	280.59	Reference (1.00)
		Statin user	63,498	1,285	204.45	0.59 (0.55–0.63)

All models were adjusted for adjusted for age, sex, residential area, household income, smoking, alcohol consumption, physical activity, hypertension, diabetes, liver cirrhosis, and abnormal alanine transaminase.

ALT, alanine aminotransferase; BMI, body mass index; HR, hazard ratio; LC, liver cirrhosis.

^∗Rates are expressed per 100,000 person-years.